Showing results (91-100 of 128) with videos related to
Sort By:
Pageof 13
Lung Cancer (Amsterdam, Netherlands)|March 2, 2025
EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancerStephanie P L Saw, Angela Takano, Siqin Zhou, et al.Science Advances|January 21, 2026
A genome-wide genetic screen reveals the P2Y2-integrin axis as a stabilizer of EGFR mutants in non-small cell lung cancer (NSCLC)Yafei Du, Wenjing Wang, Hui Chin Goh, et al.JAMA Network Open|November 5, 2021
Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung CancerStephanie P L Saw, Siqin Zhou, Jianbin Chen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 10, 2018
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLCChristian Rolfo, Philip C Mack, Giorgio V Scagliotti, et al.European Journal of Cancer (Oxford, England : 1990)|November 27, 2022
PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancerStephanie P L Saw, Win Pin Ng, Siqin Zhou, et al.The Lancet. Oncology|October 3, 2024
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trialJürgen Wolf, Maximilian Hochmair, Ji-Youn Han, et al.Lung Cancer (Amsterdam, Netherlands)|June 18, 2024
Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLCStephanie P L Saw, Yi Fen Low, Gillianne G Y Lai, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 26, 2021
Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive CohortRafal Dziadziuszko, Tony Mok, Solange Peters, et al.The Lancet. Oncology|June 12, 2021
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 studyJustin F Gainor, Giuseppe Curigliano, Dong-Wan Kim, et al.JCO Precision Oncology|October 14, 2022
Clinical and Genomic Features of HER2 Exon 20 Insertion Mutations and Characterization of HER2 Expression by Immunohistochemistry in East Asian Non-Small-Cell Lung CancerAaron C Tan, Stephanie P L Saw, Jianbin Chen, et al.Pageof 13